Michael Wang
Impact in
- Oncology top 0.05%
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments
Papers in
-
- Lymphoma Diagnosis and Treatment 311
- Genetics 196
- Chronic Lymphocytic Leukemia Research 187
- Co-authors
- Preetesh Jain (39 shared papers)Joseph L. Goldstein (5 shared papers)Michael Scott Brown (5 shared papers)Jorge Enrique Romaguera (74 shared papers)Rodney Elwood Infante (4 shared papers)Hyock Joo Kwon (4 shared papers)Luis Fayad (61 shared papers)Larry W. Kwak (42 shared papers)
- Journals
- Blood (202 papers)British Journal of Haematology (32 papers)Blood Advances (21 papers)Journal of Clinical Oncology (17 papers)Journal of Hematology & Oncology (16 papers)
- Partner nations
- United StatesChinaCanada
In The Last Decade
Michael Wang
588 papers receiving 34.5k citations
Michael Wang's Hit Papers
Peers
Comparison fields: 5 of 175
- Oncology 18.5k
- Hematology 7.8k
- Genetics 6.8k
- Pathology and Forensic Medicine 10.2k
- Immunology 5.8k
Countries citing papers authored by Michael Wang
This map shows the geographic impact of Michael Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wang more than expected).
Fields of papers citing papers by Michael Wang
This network shows the impact of papers produced by Michael Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wang. The network helps show where Michael Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 611 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Hit paper breakdown → | 2020 | 1909 |
| 2 | Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Hit paper breakdown → | 2020 | 1743 |
| 3 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Hit paper breakdown → | 2020 | 1440 |
| 4 | Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Hit paper breakdown → | 2014 | 1386 |
| 5 | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Hit paper breakdown → | 2013 | 1373 |
| 6 | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Hit paper breakdown → | 2014 | 1125 |
| 7 | Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America Hit paper breakdown → | 2007 | 1062 |
| 8 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials Hit paper breakdown → | 2019 | 695 |
| 9 | T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma Hit paper breakdown → | 2016 | 679 |
| 10 | T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma Hit paper breakdown → | 2018 | 668 |
| 11 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study Hit paper breakdown → | 2011 | 652 |
| 12 | Seroepidemiology of Human Polyomaviruses Hit paper breakdown → | 2009 | 613 |
| 13 | A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Hit paper breakdown → | 2012 | 567 |
| 14 | Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol Hit paper breakdown → | 2009 | 559 |
| 15 | 2005 | 456 | |
| 16 | 2004 | 452 | |
| 17 | 2008 | 394 | |
| 18 | Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study Hit paper breakdown → | 2021 | 365 |
| 19 | Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2017 | 360 |
| 20 | 1999 | 355 |
About Michael Wang
Michael Wang is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Immunology, having authored 611 papers that have together received 35.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (311 papers), Chronic Lymphocytic Leukemia Research (187 papers), Multiple Myeloma Research and Treatments (116 papers), CAR-T cell therapy research (103 papers), Viral-associated cancers and disorders (70 papers), Protein Degradation and Inhibitors (60 papers), Ubiquitin and proteasome pathways (40 papers) and Cancer Treatment and Pharmacology (28 papers). The work is most often cited by research in Oncology (18.5k citations), Hematology (7.8k citations), Genetics (6.8k citations), Pathology and Forensic Medicine (10.2k citations) and Immunology (5.8k citations). Michael Wang has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Preetesh Jain, Joseph L. Goldstein, Michael Scott Brown, Jorge Enrique Romaguera, Rodney Elwood Infante, Hyock Joo Kwon, Luis Fayad, Larry W. Kwak, Robert L. Garcea and David Samuel DiCapua Siegel. Their work appears in journals such as Blood, British Journal of Haematology, Blood Advances, Journal of Clinical Oncology and Journal of Hematology & Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.